Cyberonics Inc

Cyberonics — Merger or Acquisition (May 2015)

9 slides from Cyberonics's merger presentation, May 19, 2015

  1. Slide 1: Cyberonics International Sales Meeting

    Cyberonics International Sales Meeting Greg Browne & André-Michel Ballester Austria, Kitzbühel – 19 May 2015

  2. Slide 2: Compelling Strategic Rationale

    Compelling Strategic Rationale Creates Global Leader in the large and growing markets for Cardiac Surgery and Neuromodulation and a leading innovator in Cardiac Rhythm Management 1 Generates opportunities in three multi-billion dollar product categories: heart failure, sleep apnea and percutaneous m

  3. Slide 3: Highly complementary businesses...

    Highly complementary businesses... Business Unit Geography Revenue: Neuromodulation 100% International 20% US 80% CRM 33% US 23% Revenue: $292M Revenue: $998M CRM 33% US 23% Cardiac Surgery 67% International 77% 1) LTM figures as of January 23rd 2015 for Cyberonics. LTM figures as of December 31st 2

  4. Slide 4: ...leading to diversified product portfolio and broader geographical reach

    ...leading to diversifies product portfolio and broader geographical reach pro forma 2014 revenues by geography1 pro forma 2014 revenues by business1 Rest World 21% Neuromodulation 23% Europe 43% Cardiac Surgery 52% US 36% CRM 25% 1) LTM figures as of January 23rd 2015 for Cyberonics. LTM figures as

  5. Slide 5: Leadership in Large and Growing Markets

    CARDIAC SURGERY NEUROMODULATION CRM Market Position Cardiopulmonary global leader #1 in Heart-lung machines #1 in Oxygenators Leading player in mechanical and tissue valves On-going roll out of new products Long-standing leader in Neuromodulation #1 position in devices for epilepsy Pioneer in VNS tr

  6. Slide 6: Winning Together in New Markets

    Heart Failure Sleep Apnea MIS Mitral Market Opportunity > $1 billion > $1 billion > $1 billion Cyberonics Programs VITARIATM Investment in ImThera Ownership of Apnex assets and IP (OSA) N/A Sorin Programs EquiliaTM INTENSE Ultima Investment in Respicardia (CSA) Investments in: Caisson, High Life Car

  7. Slide 7: Operational Synergies Driving Significant Incremental Value

    Heart Failure Neuromodulation Revenue Manufacturing R&D Optimization Corporate Overhead Capitalizing on market relationships and technology capabilities with wider product range Cyberonics’ leverage of Sorin’s global commercialization network Increased purchasing power and improved manufacturing uti

  8. Slide 8: Our New Company: Who We Are Together

    Our New Company: Who We Are Together . Bringing together shared core values Focus on customers People we serve Physicians Payers – hospitals and healthcare systems Focus on employees, quality, and goal achievement Focus on meaningful innovation and technology Resulting shareholder value Establishing

  9. Slide 9: Sorin and Cyberonics

    Sorin and Cyberonics The combined NewCo will be among the largest med-tech companies globally Combined NewCo will be amongst the top 25 valued med-tech companies globally Our combined annual revenues will be more than $1.3B NewCo will be a global company with a global footprint; with operations in m

Cyberonics — Merger or Acquisition (May 2015) on 6ix